Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.

as reflected in EPA's announcement that "Lead and Lead Compounds" is on its list of candidate chemical substances currently being considered for future prioritization actions under TSCA." The EPA ...

is pleased to announce that its lead compound (RSBT-001) reduced inflammatory biomarkers and mediators of fibrosis in a human precision cut lung slices study. RSBT-001 was evaluated in three ...

The compounds target NLRP3 systemically in the periphery or directly in the brain. The company’s lead compound is NT-0796, a small molecule with differentiated chemistry that is currently in a ...